Targeted therapies in the treatment of renal cell carcinoma.
The management of renal cell carcinoma (RCC) has undergone rapid and radical evolution over the last few years. An improved understanding of the underlying biology of RCC has led to the approval of several new therapies directed against specific and relevant biological targets, so-called "targeted therapies." These highly effective treatments are now entering routine use, however many questions still remain as to how best to use these agents and integrate them into the broader therapeutic armamentarium. This review summarizes the major published clinical trials of the new agents, discusses the controversies and research questions that have arisen as a result, and considers some of the issues that remain.
Pezaro
Carmel
C
Ludwig Institute Oncology Unit, Austin Health, Melbourne, Victoria, Australia.
Davis
Ian D
ID
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000187:drug effects; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D012039:Regional Blood Flow / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors